Lexicon Pharma (LXRX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.16 +0.47%
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- After-Hours Stock Movers: FDX, CBRS, NKE
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
